Adipotide (FTPP) 10mg: Dosage, Reconstitution & Research Protocol Guide

Adipotide (FTPP) 10mg Vial Specifications

Peptide

Adipotide (FTPP) (10 mg Vial) (NNMT inhibitor)

Vial Content

10 mg total peptide

Category

Metabolic / Weight Loss

Administration Method

Subcutaneous injection

Common Use Case

Aggressive fat loss and adipose tissue reduction protocols

Adipotide (FTPP) Mechanism of Action

Adipotide (also known as FTPP or Prohibitin-TP01) is a chimeric peptidomimetic consisting of two functional domains: a targeting peptide sequence (CKGGRAKDC) that selectively binds to prohibitin receptors expressed on the surface of blood vessels supplying white adipose tissue, and a pro-apoptotic peptide (D(KLAKLAK)2) that triggers mitochondrial membrane disruption and programmed cell death. By destroying the vasculature feeding fat deposits, Adipotide causes adipose tissue to undergo ischemic necrosis and subsequent resorption. This vascular-targeting approach represents a fundamentally different mechanism than metabolic or lipolytic fat-loss compounds.

Adipotide (FTPP) Research Findings and Observed Outcomes

Findings and reported areas of study for Adipotide (FTPP) (10 mg Vial) include:

• Rapid and substantial reduction in adipose tissue mass
• Targeted action on fat tissue vasculature rather than systemic metabolism
• Potential for permanent fat cell reduction in treated areas
• Diet and exercise-independent mechanism of action

These observations are discussed for research and educational reference only and are not medical claims.

Adipotide (FTPP) 10mg Supplies for Reconstitution and Handling

• •Sterile syringes (≥3 mL capacity for diluent)
• •Insulin syringes (typically 29–31 gauge)
• •Bacteriostatic water
• •Alcohol prep pads
• •Sharps container
• •Labels or marker for dating reconstituted vials

Supplies listed are for laboratory handling and research preparation purposes only.

Adipotide (FTPP) Injection Route, Frequency and Timing

Subcutaneous injection is standard. Rotate injection sites. Kidney function monitoring is essential due to the compound's renal clearance and apoptotic metabolites.

Adipotide (FTPP) Dosage Ranges

The ranges below pair the listed dose with the draw volume for this product strength.

Adipotide (FTPP) 10mg Dosage to Syringe Units

Based on reconstitution below

This dosing table is unique to the 10 mg vial. Units refer to markings on a standard U-100 insulin syringe (1 unit = 0.01 mL).

Adipotide (FTPP) 10mg Duration by Research Dose

At common research doses, one 10 mg vial of Adipotide (FTPP) typically supports:

Cycles of 4–6 weeks are commonly referenced in research literature, followed by extended washout periods to allow kidney function recovery.

Adipotide (FTPP) 10mg Reconstitution With Bacteriostatic Water

This section applies specifically to the Adipotide (FTPP) (10 mg Vial).

Recommended Diluent

Bacteriostatic water

Diluent Volume

2 mL

Final Concentration

5 mg/mL (5,000 mcg/mL)

Adipotide (FTPP) and Compatible Research Pairings

In research settings, Adipotide (FTPP) (10 mg Vial) is sometimes paired with peptides such as:

• BPC-157: For potential nephroprotective and tissue-repair support
• TB-500: For systemic recovery and healing during aggressive protocols

Stacking with other fat-loss compounds (AOD-9604, GH secretagogues) has not been studied and may increase systemic stress. Protective peptides are more commonly paired with Adipotide.

Supporting Factors for Adipotide (FTPP) Research

Factors recorded alongside this protocol include:

• Maintain excellent hydration (3–4+ liters/day) to support renal clearance
• Regular kidney function monitoring (BUN, creatinine, GFR)
• Adequate protein intake to support tissue remodeling
• Moderate physical activity; avoid extreme metabolic stress during cycles

These factors can affect how research observations are interpreted.

Adipotide (FTPP) 10mg Tolerability Notes

Adipotide carries significant safety considerations due to its mechanism of action. The apoptotic peptide component, while targeted, can produce off-target effects. Close monitoring is essential.

Some individuals report:

• Mild injection site reactions (redness, swelling)
• Kidney stress or transient renal impairment
• Dehydration symptoms
• Fatigue and malaise during treatment
• Potential for off-target vascular effects

Adipotide (FTPP) 10mg Storage Requirements

Unreconstituted

Store frozen at -20°C or refrigerated at 2–8°C

Reconstituted

Refrigerate at 2–8°C (35.6–46.4°F)

Post-Mix Stability

Up to 2–3 weeks when properly refrigerated

• Protect from light at all times.
• Do not freeze reconstituted solution.
• Discard if solution becomes cloudy, discolored, or contains particles.
• Use sterile technique when accessing the vial.
• Adipotide is sensitive to repeated freeze-thaw cycles.

This peptide is generally not recommended for:

• Pregnant or breastfeeding individuals
• Those with kidney disease or impaired renal function
• Individuals with cardiovascular disease or vascular disorders
• Those with autoimmune conditions
• Anyone with a history of blood clotting disorders
• Anyone advised otherwise by a healthcare professional

Adipotide (FTPP) 10mg Purchasing and Research Supply Notes

Before ordering Adipotide (FTPP) (10 mg Vial), review the product label, available testing documents, and storage instructions.

Check the ResearchLabs listing for:

• Available testing documents
• Product strength and concentration
• Storage and handling instructions
• Current product availability

Confirm the product strength and storage requirements before ordering. Products are for laboratory research only and are not for human consumption.